Serum bone biomarkers were suppressed by 1D11 administration, building on observations made by Tang et al., who suggested that inhibition of the TGF‐β pathway with a TGF‐β type I receptor inhibitor restored the coupling between osteoblasts and osteoclasts.(10) BFR/BS and MAR were decreased with 1D11 treatment (Fig. 7), an observation shared by Liu et al., where 1D11 decreased both in a dose‐responsive fashion in a high‐turnover renal osteodystrophy model.(13) Suppression of RUNX2, CTx‐1, and OCN by 1D11 with a corresponding increase in ALP suggests an effect of the antibody on bone turnover. Here, TGFB1 is linked to renal osteodystrophy.